Welcome to our dedicated page for Chemomab Therapeutics news (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics stock.
Chemomab Therapeutics Ltd. (CMMB) generates news primarily as a clinical-stage biotechnology company developing nebokitug, a monoclonal antibody targeting the soluble protein CCL24 in fibro-inflammatory diseases. Much of the company’s news flow centers on clinical data, regulatory interactions and scientific presentations related to primary sclerosing cholangitis (PSC), a rare and progressive liver disease with no effective medical therapy other than liver transplantation in advanced cases.
Investors and observers following Chemomab news can expect detailed updates on the Phase 2 SPRING trial of nebokitug in PSC, including results from the double-blind, placebo-controlled portion and the open label extension, where patients received nebokitug for up to 48 weeks. Press releases describe safety and tolerability findings, changes in biomarkers such as ELF score, PRO-C3 and liver stiffness measurements, and analyses in subgroups with moderate or advanced fibrosis. These reports often highlight biomarker patterns that are associated with PSC disease progression and transplant-free survival.
Chemomab’s news also covers regulatory milestones, such as outcomes of End-of-Phase 2 meetings with the FDA, alignment on a single Phase 3 registration trial design using a composite of clinically relevant events, and agreements on Chemistry, Manufacturing and Controls (CMC) and nonclinical toxicology requirements. Additional announcements address Orphan Drug and Fast Track designations for nebokitug, as well as the status of an open U.S. IND for systemic sclerosis.
Another recurring theme in Chemomab’s news releases is its scientific and investor outreach. The company reports oral and poster presentations at major liver and gastroenterology meetings, including Digestive Disease Week, BSG Live, AASLD The Liver Meeting and EASL congresses, where nebokitug data and CCL24-related mechanisms are discussed. Chemomab also announces participation in rare disease summits and global investment conferences, along with corporate updates tied to quarterly financial results, patent awards and capital markets activities such as at-the-market equity offerings or ADS ratio adjustments.
Readers of the CMMB news page on Stock Titan can use this stream of clinical, regulatory and corporate announcements to track Chemomab’s progress with nebokitug in PSC and other fibro-inflammatory indications, as well as to monitor key events that may influence the company’s development plans and regulatory trajectory.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a biotechnology firm specializing in innovative therapeutics for fibro-inflammatory diseases, announced its participation in the Aegis 2023 Virtual Investor Conference from May 2 to May 4, 2023. Chemomab's management will present a corporate overview on May 3, 2023, at 9:00 AM EDT. The event will be held virtually, and investors can access the webcast through a provided link.
Additionally, Chemomab's corporate development team will attend the BIO International Convention's One-on-One Partnering™ event in Boston from June 5 to June 8, 2023. They encourage registered attendees to schedule meetings via an online portal.
The company focuses on creating therapies like CM-101, a monoclonal antibody aimed at treating severe fibro-inflammatory diseases, backed by ongoing Phase 2 trials.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) announced its participation in several scientific conferences during April and May 2023. Key events include the British Society for Rheumatology Annual Conference from April 24-26, where Chemomab will present an oral presentation on CCL24 serum concentration and its relevance in systemic sclerosis. The second event is the EASL Monothematic Conference on Biliary Fibrosis from May 12-13, highlighting a poster presentation on the role of CCL24 in cholestatic disease. Additionally, Chemomab's corporate development team will attend the BIO International Convention in Boston from June 5-8, focusing on partnership opportunities. Chemomab aims to advance innovative therapeutics for fibro-inflammatory diseases, particularly through its monoclonal antibody CM-101, which targets CCL24.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotechnology company, will hold a webcast and conference call on May 11, 2023, at 8:00 am ET to discuss its first quarter 2023 financial results and provide a corporate update. This event replaces a previous update originally set for April 17, 2023. During the call, the management team will review the company's performance, recent developments, and host a Q&A session. A replay will be available on their website for 90 days. Chemomab focuses on developing therapeutics for fibro-inflammatory diseases and has seen promising results from its lead product, CM-101, in various ongoing studies.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) will hold a Corporate Update on April 17, 2023, at 8:00 am Eastern Time. This replaces a previously scheduled webcast on March 31, 2023. The management team will review recent developments and answer questions from investors. Chemomab focuses on innovative therapies for fibro-inflammatory diseases, with CM-101 showing promise in trials for liver fibrosis and severe lung injury in COVID-19 patients. A Phase 2 trial for primary sclerosing cholangitis is ongoing, and a similar trial for systemic sclerosis is expected to open mid-2023.
Chemomab Therapeutics (Nasdaq: CMMB) will present its Q4 and full-year 2022 financial results on March 31, 2023, at 8:00 am Eastern Time. The management team will review the company’s performance and discuss future developments during the call, which includes a live question-and-answer session. Notably, the company focuses on developing therapeutics to address fibro-inflammatory diseases. Their key product, CM-101, aims to treat severe diseases related to fibrosis and inflammation, with recent positive results from clinical studies. A replay of the event will be available for 90 days on their website.